By InvitationNot Applicable

Telemedicine Self-examination of Speech and Memory for Rapid Detection of Cognitive Impairments Using Machine Learning Methods

Czechia500 participantsStarted 2023-09-01

Plain-language summary

Early cognitive disorders diagnosis is becoming increasingly important due to population aging. The most common causes include Alzheimer's disease and frontotemporal dementia. These diseases are also manifested by changes in speech. NLP allows us to identify and classify these changes. The project aims to develop a web application for self-assessment and automated detection of cognitive disorders from speech. The application will have a form of a dialogue system using machine learning methods. The novelty of this approach is the possibility of an efficient self-assessment of a wide spectrum of the Czech population from their homes and an automated evaluation of test results. Early detection can be followed by a more detailed diagnosis and adequate treatment.

Who can participate

Age range

40 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria for the group of healthy participants: * age over 45 years * Czech as the native language * must meet the criteria in a questionnaire with questions focused on a history of brain injury or psychiatric history or medication use * must achieve normal scores on questionnaires assessing mood Inclusion Criteria for the group of patients: \- be diagnosed with mild neurocognitive impairment (MCI) or neurocognitive disorder (dementia) according to the international DSM-5 criteria

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

The difference in results between groups of patients with cognitive impairment and healthy individuals in individual parts of our experimental neuropsychological battery Diagnostic Test: Digitial Diagnostics of Dementia (DDD)

Timeframe: Through study completion, an average of 2 years

Correlation of the results of our experimental battery (DDD) with RBANS

Timeframe: Through study completion, an average of 2 years

Correlation of the results of our experimental battery (DDD) with MAST

Timeframe: Through study completion, an average of 2 years

Correlation of the results of our experimental battery (DDD) with ALBA

Timeframe: Through study completion, an average of 2 years

Correlation of the results of our experimental battery (DDD) with POBAV

Timeframe: Through study completion, an average of 2 years

Trial details

NCT IDNCT07558785

SponsorFaculty Hospital Kralovske Vinohrady

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2025-12-31

View on ClinicalTrials.gov More Mild Cognitive Impairment (MCI) trials

Plain-language summary

Who can participate

Age range

40 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Timeframe: Through study completion, an average of 2 years

Correlation of the results of our experimental battery (DDD) with RBANS

Timeframe: Through study completion, an average of 2 years

Correlation of the results of our experimental battery (DDD) with MAST

Timeframe: Through study completion, an average of 2 years

Correlation of the results of our experimental battery (DDD) with ALBA

Timeframe: Through study completion, an average of 2 years

Correlation of the results of our experimental battery (DDD) with POBAV

Timeframe: Through study completion, an average of 2 years